Provided by Tiger Fintech (Singapore) Pte. Ltd.

Agios Pharmaceuticals

40.00
-0.3500-0.87%
Post-market: 40.000.00000.00%16:32 EDT
Volume:824.55K
Turnover:33.30M
Market Cap:2.32B
PE:3.49
High:41.19
Open:40.70
Low:39.96
Close:40.35
Loading ...

Company Profile

Company Name:
Agios Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
487
Office Location:
88 Sidney Street,Cambridge,Massachusetts,United States
Zip Code:
02139
Fax:
- -
Introduction:
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
Brian Goff
Chief Executive Officer and Director
Jacqualyn A. Fouse
Chairman of the Board
Catherine Owen
Independent Director
Cynthia Smith
Independent Director
David Scadden
Independent Director
Jeffrey D. Capello
Independent Director
Kaye Foster Cheek
Lead Independent Director
Maykin Ho
Independent Director
Rahul D. Ballal
Independent Director
Jay Backstrom
Director

Shareholders

Name
Position
Brian Goff
Chief Executive Officer and Director
Cecilia Jones
Chief Financial Officer
James Burns
Chief Legal Officer
Krishnan Viswanadhan
Chief Corporate Development and Strategy Officer
Sarah Gheuens
Chief Medical Officer and Head of Research and Development
T. J. Washburn
Principal Accounting Officer, Vice President and Controller
Tsveta Milanova
Chief Commercial Officer